Skip to content

Study · Randomized controlled trial · n = 9,901 · 2019

4 results

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM and 25 more

Show all authors

Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T

Lancet (London, England)9 Jun 2019Cited by 467 (Europe PMC)

PMID31189509 (opens in a new tab)DOI10.1016/s0140-6736(19)31150-x (opens in a new tab)PepBankPUB-31189509
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In T2D patients with cardiovascular disease or risk factors, dulaglutide reduced the composite renal outcome versus placebo.

    In plain wordsIn T2D patients with cardiovascular disease or risk factors, dulaglutide reduced the combined kidney outcome compared with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseComposite renal outcome
    Study

    n = 9,901

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg weekly · subcutaneous · Median follow-up 5.4 yearsAs given in this study (human).

    Measurements

    Renal outcome
    17.1%
    dulaglutide
    Renal outcome
    19.6%
    placebo
    Hazard ratio
    0.85 ratio
    dulaglutide versus placebo
    Renal outcome
    848 participants
    dulaglutide
    Renal outcome
    970 participants
    placebo
    Incidence rate
    3.5 per 100 person-years
    dulaglutide
    Incidence rate
    4.1 per 100 person-years
    placebo

    Source sentences

    Summary
    During a median follow-up of 5·4 years (IQR 5·1-5·9) comprising 51 820 person-years, the renal outcome developed in 848 (17·1%) participants at an incidence rate of 3·5 per 100 person-years in the dulaglutide group and in 970 (19·6%) participants at an incidence rate of 4·1 per 100 person-years in t…
    2 context sentences
    Summary · context
    Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1·5 mg) or placebo and followed up at least every 6 months for outcomes.
    Summary · context
    In this exploratory analysis, we investigate the renal component of the composite microvascular outcome, defined as the first occurrence of new macroalbuminuria (UACR >33·9 mg/mmol), a sustained decline in eGFR of 30% or more from baseline, or chronic renal replacement therapy.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In T2D patients with cardiovascular disease or risk factors, dulaglutide reduced new macroalbuminuria versus placebo.

    In plain wordsIn T2D patients with cardiovascular disease or risk factors, dulaglutide reduced new severe urine albumin elevation compared with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseNew macroalbuminuria
    Study

    n = 9,901

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg weekly · subcutaneous · Median follow-up 5.4 yearsAs given in this study (human).

    Measurements

    Hazard ratio
    0.77 ratio
    new macroalbuminuria versus placebo

    Source sentences

    Summary
    The clearest effect was for new macroalbuminuria (HR 0·77, 95% CI 0·68-0·87; p<0·0001), with HRs of 0·89 (0·78-1·01; p=0·066) for sustained decline in eGFR of 30% or more and 0·75 (0·39-1·44; p=0·39) for chronic renal replacement therapy.
    2 context sentences
    Summary · context
    Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1·5 mg) or placebo and followed up at least every 6 months for outcomes.
    Summary · context
    In this exploratory analysis, we investigate the renal component of the composite microvascular outcome, defined as the first occurrence of new macroalbuminuria (UACR >33·9 mg/mmol), a sustained decline in eGFR of 30% or more from baseline, or chronic renal replacement therapy.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In T2D patients with cardiovascular disease or risk factors, sustained eGFR decline did not differ significantly between dulaglutide and placebo.

    In plain wordsIn T2D patients with cardiovascular disease or risk factors, sustained kidney filtration decline did not differ significantly between dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSustained eGFR decline of at least 30%
    Study

    n = 9,901

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg weekly · subcutaneous · Median follow-up 5.4 yearsAs given in this study (human).

    Measurements

    Hazard ratio
    0.89 ratio
    sustained eGFR decline versus placebo

    Source sentences

    Summary
    The clearest effect was for new macroalbuminuria (HR 0·77, 95% CI 0·68-0·87; p<0·0001), with HRs of 0·89 (0·78-1·01; p=0·066) for sustained decline in eGFR of 30% or more and 0·75 (0·39-1·44; p=0·39) for chronic renal replacement therapy.
    2 context sentences
    Summary · context
    Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1·5 mg) or placebo and followed up at least every 6 months for outcomes.
    Summary · context
    In this exploratory analysis, we investigate the renal component of the composite microvascular outcome, defined as the first occurrence of new macroalbuminuria (UACR >33·9 mg/mmol), a sustained decline in eGFR of 30% or more from baseline, or chronic renal replacement therapy.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In T2D patients with cardiovascular disease or risk factors, chronic renal replacement therapy did not differ significantly between dulaglutide and placebo.

    In plain wordsIn T2D patients with cardiovascular disease or risk factors, long-term kidney replacement treatment did not differ significantly between dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeChronic renal replacement therapy
    Study

    n = 9,901

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg weekly · subcutaneous · Median follow-up 5.4 yearsAs given in this study (human).

    Measurements

    Hazard ratio
    0.75 ratio
    chronic renal replacement therapy versus placebo

    Source sentences

    Summary
    The clearest effect was for new macroalbuminuria (HR 0·77, 95% CI 0·68-0·87; p<0·0001), with HRs of 0·89 (0·78-1·01; p=0·066) for sustained decline in eGFR of 30% or more and 0·75 (0·39-1·44; p=0·39) for chronic renal replacement therapy.
    2 context sentences
    Summary · context
    Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1·5 mg) or placebo and followed up at least every 6 months for outcomes.
    Summary · context
    In this exploratory analysis, we investigate the renal component of the composite microvascular outcome, defined as the first occurrence of new macroalbuminuria (UACR >33·9 mg/mmol), a sustained decline in eGFR of 30% or more from baseline, or chronic renal replacement therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Eli Lilly and Companyn = 9,90122 Jul 2011 to 21 Aug 2018

Cardiovascular Disease · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.